Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Regimens for Onchocerciasis
NCT06070116Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2024
- Primary completion
- Sep 2026
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of moxidectin, diethylcarbamazine, CHILD-IVITAB, albendazole in onchocerciasis, sponsored by Washington University School of Medicine. Started Apr 2024; status: active, not recruiting.
02
Drugs
moxidectindiethylcarbamazineCHILD-IVITABalbendazole
03
Conditions
onchocerciasis
Beyond the preview
Go deeper on NCT06070116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06070116.